Quercetin, Fisetin and Senolytic Supplements: Evidence So Far

What "senolytic" means

Senescent cells are aging cells that stop dividing but stay in tissues and release inflammatory signals. "Senolytics" are substances tested for clearing them. Two plant flavonoids, quercetin and fisetin, are discussed as senolytics. The key point for readers is that the human data are mostly for quercetin combined with a prescription-type drug, dasatinib, not for supplements alone. For the cell biology, see cellular senescence explained. Nothing here is a recommendation. Senolytic use is not approved for aging, and no use guidance is given.

Evidence labels: preclinical (cells or animals only), promising but limited, mixed, insufficient evidence, marketing claim.

Evidence at a glance

Fisetin

In a screen of 10 flavonoids on senescent cells, fisetin was the most potent senolytic. In old mice, fisetin given late in life reduced age-related pathology and extended median and maximum lifespan. It also reduced senescence in a subset of cells in human fat tissue samples. [1] These are animal and tissue findings and do not show benefit in people.

Human trials are only now being reported. A 2026 trial protocol says evidence from randomized trials in humans is limited, and plans to give 100 mg of oral fisetin or placebo daily for 7 weeks to adults 50 and over, measuring an inflammation marker and adverse events. [2] A phase II trial plan in 88 postmenopausal breast cancer survivors notes that no study had yet tested senolytics on physical function in this group. [3] We found no published results from either; protocols are not evidence of benefit. Fisetin supplement quality, and dose and safety in people, are not established by the sources read.

Dasatinib plus quercetin in humans

Dasatinib is a drug; it is not a supplement, and this page gives no guidance on it.

• Diabetic kidney disease. An open-label pilot in 9 people gave D+Q for 3 days. Fat-tissue senescent cell markers fell within 11 days, and some blood inflammatory factors fell. [4] There was no comparison group, and the outcome was a biomarker. Authors disclosed that patents on senolytic drugs are held by Mayo Clinic. [4]
• Idiopathic pulmonary fibrosis (open-label). In 14 people, retention was 100% and one serious adverse event was reported. Walking distance, gait speed and chair-stand time improved, while lung function and frailty index did not change. [5]
• Idiopathic pulmonary fibrosis (randomized pilot). In 12 people, there were no serious adverse events related to D+Q, but sleep disturbances and anxiety appeared more in the D+Q group (4 of 6 versus 0 of 6), and physical function did not appear to differ meaningfully between groups. [6] The authors also disclosed patent interests in senolytic drugs. [6]
• Systematic review. A 2026 review of six completed human studies found preliminary improvements in selected functional outcomes and biomarkers, mostly mild adverse events, small samples and short follow-up. It concluded evidence is insufficient to establish clinical efficacy or long-term safety and that these approaches are investigational. [7]

The first open-label signal on function was not reproduced in the randomized pilot, which is why we call the whole body promising but limited.

Quercetin alone

Our search found reviews of quercetin on cholesterol, blood pressure and glucose, but no human trial testing quercetin alone for clearing senescent cells. Proper evidence not found for that use. For the ingredient and general safety, see polyphenols, quercetin and resveratrol.

How to judge claims

Phrases like "clears zombie cells" are marketing claims unless backed by human outcome data. Compare with senolytic drugs: dasatinib-quercetin and trials and senescence, senolytics and autophagy.